• Journal of Pharmaceutical Investigation
• /
• 제39권2호
• /
• pp.141-147
• /
• 2009

The purpose of this study was to evaluate the bioequivalence of two nateglinide tablets, $PASTIC^{(R)}$ tablet (ILDONG Pharm. Co., Ltd., Seoul, Korea, reference drug) and $GLUNATE^{(R)}$ tablet (ILHWA. Co., Ltd., Seoul, Korea, test drug), according to the guidelines of Korea Food and Drug Administration (KFDA). Thirty-five healthy male volunteers, $23.1{\pm}2.3$ years in age and $69.2{\pm}8.8\;kg$ in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After a tablet containing 90 mg of nateglinide was orally administrated, blood was taken at predetermined time intervals over a period of 8 hr and concentrations of nateglinide in plasma were monitored using LC-MS/MS. Pharmacokinetic parameters such as AUCt (the area under the plasma concentration-time curve from time 0 to 8 hr), $C_{max}$ (maximum plasma drug concentration) and $TC_{max}$ (time to reach $CC_{max}$) were calculated and analysis of variance (ANOVA) test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$ and $C_{max}$ and untransformed $T_{max}$. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $GLUNATE^{(R)}/PASTIC^{(R)}$ were ${\log}1.0782{\sim}{\log}1.1626$ and ${\log}0.9621{\sim}{\log}1.1679$, respectively. Since these values were within the acceptable bioequivalence intervals of ${\log}0.80{\sim}{\log}1.25$, recommended by KFDA, it was concluded that $GLUNATER^{(R)}$ tablet was bioequivalent to $PASTIC^{(R)}$ tablet, in terms of both rate and extent of absorption.

• 한국산학기술학회논문지
• /
• 제18권1호
• /
• pp.506-512
• /
• 2017

본 연구의 목적은 나테글리니드를 함유하는 제형에 있어서 약물방출 속도 및 생체이용률을 개선하는 것이다. 이를 위해, 약물의 결정형의 선택 및 입자 크기의 최적화를 진행하였으며, 약물의 pH 의존적인 용해도를 극복하기 위하여 제형에 pH 조절제를 포함하여 pH에 따른 약물의 용출속도 저하를 개선하고자 하였다. 또한 개선된 약물방출 속도 확인을 위하여 용출시험을 실시하였다. 약물의 결정형에 따른 용출속도를 비교한 결과로는 H-type의 원료가 B-type에 비해 60분에서의 용출률이 6.2% 더 빠르게 나타나는 것을 확인하였으며, 약물의 입도 차에 따라서는 평균입도 $1.13{\mu}m$인 원료가 $2.28{\mu}m$인 원료에 비해 60분에서의 용출률이 약 20% 빠르게 나타나는 것을 확인할 수 있었다. 또한 pH 조절제로서 유기산인 푸마르산을 제형에 포함시킨 결과, 용출시험 60분 경과 후 50% 이상의 용출 속도 개선을 확인할 수 있었다. 결론적으로, 약물의 결정형 및 입도의 조절을 통해 나테글리니드의 용출 속도를 증가시킬 수 있으며, pH 조절제로서 푸마르산을 제형에 적용할 경우 용출속도 개선 측면에서 동반상승 효과를 얻을 수 있다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제17권6호
• /
• pp.493-497
• /
• 2013

We have recently demonstrated that some anti-diabetic drugs such as biguanide and thizolidinediones administered centrally modulate the blood glucose level, suggesting that orally administered anti-diabetic drugs may modulate the blood glucose level by acting on central nervous system. The present study was designed to explore the possible action of another class of anti-diabetic drugs, glinidies, administered centrally on the blood glucose level in ICR mice. Mice were administered intracerebroventricularly (i.c.v.) or intrathecally (i.t.) with 5 to $30{\mu}g$ of repaglinide or nateglinide in D-glucose-fed and streptozotocin (STZ)-treated models. We found that i.c.v. or i.t. injection with repaglinide dose-dependently attenuated the blood glucose level in D-glucose-fed model, whereas i.c.v. or i.t. injection with nateglinide showed no modulatory action on the blood glucose level in D-glucose-fed model. Furthermore, the effect of repaglinide administered i.c.v. or i.t. on the blood glucose level in STZ-treated model was studied. We found that repaglinide administered i.c.v. slightly enhanced the blood glucose level in STZ-treated model. On the other hand, i.t. injection with repaglinide attenuated the blood glucose level in STZ-treated model. The plasma insulin level was enhanced by repaglinide in D-glucose-fed model, but repaglinide did not affect the plasma insulin level in STZ-treated model. In addition, nateglinide did not alter the plasma insulin level in both D-glucose-fed and STZ-treated models. These results suggest that the anti-diabetic action of repaglinide appears to be, at least, mediated via the brain and the spinal cord as revealed in both D-glucose fed and STZ-treated models.